Core Viewpoint - Tevogen Bio has filed a new patent for its T cell vaccine, which utilizes its proprietary Tevogen.AI-powered PredicTcell technology to stimulate a T cell response, targeting the entire viral genome to mitigate mutation risks [1][2][8] Group 1: Vaccine Development - The T cell vaccine aims to provide a broader immune response by targeting the entire viral genome, similar to the lead product candidate TVGN 489, thus reducing the risk of mutations evading immune detection [2][8] - The development of this vaccine will not affect the previously announced topline forecasts of $1 billion each for Tevogen Bio Oncology and Specialty Care [3] Group 2: Strategic Focus - The current focus of the T cell vaccine development is on national security and protecting the U.S. military against biological threats, with potential for broader applications in the future [4] - The company emphasizes the importance of public trust and transparency throughout the vaccine development process [4] Group 3: Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company that develops precision T cell therapies to address significant unmet needs in infectious diseases and cancers [5] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents [5][6]

WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, recently joined industry leaders at Proskauer's AI discussion panel, "Attuned AI: Shaping AI to Empower Your Industry," held on March 6, 2025, in New York City. Along with Mittul Mehta, the event featured Brooker Belcourt, General Manager of Finance from Perplexity, and ...

Tevogen Bio CIO Speaking at Proskauer's Discussion Panel on AI Tevogen Bio CIO Speaking at Proskauer's Discussion Panel on AI WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, recently joined industry leaders at Proskauer’s AI discussion panel, "Attuned AI: Shaping AI to Empower Your Industry," held on March 6, 202 ...

On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. TVGN, a clinical-stage immunotherapy company.The company’s lead pipeline product, TVGN-489, is a SARS-CoV-2-specific therapy.Tevogen’s pipeline includes preclinical programs targeting Epstein-Barr virus-associated lymphomas (TVGN -930), human papillomavirus-related cervical cancer (TVGN -920), multiple sclerosis (TVGN -601), and HPV-related mouth and throat cancer (TVGN-960).Also Read: Amazon To Launch AI Reasoning Model In June, Re ...

Core Insights - Tevogen Bio's Founder and CEO, Ryan Saadi, has been recognized in the 2025 NJBIZ Power 100 for his influence in New Jersey's business landscape [1] - The company focuses on developing affordable and accessible T cell therapies for viral infections and cancers using its proprietary ExacTcell technology [2][7] - Tevogen Bio aims to challenge high drug development costs with an efficient business model, emphasizing sustainability and patient accessibility [3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes to create precision T cell therapies for infectious diseases and cancers [4] - The company has reported positive safety data from its proof-of-concept clinical trial, with key intellectual property assets wholly owned and not subject to third-party licensing [4] - Tevogen Bio's leadership believes that personalized therapeutics and innovative business models are essential for sustaining medical innovation [5] Recent Developments - A proof-of-concept trial utilizing ExacTcell technology yielded highly positive results, which have been published in Blood Advances [2][7] - The launch of Tevogen.AI and a partnership with Microsoft are significant steps towards making therapies more accessible [2][7]

Core Viewpoint - Tevogen Bio aims to set new efficiency standards in the biotech industry, demonstrating that innovation and cost-effectiveness can coexist while addressing rising drug development costs and aligning with drug price reform efforts [1][2]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified precision T cell therapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases and cancers, targeting significant unmet needs in large patient populations [3]. - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents, with some related to artificial intelligence [3]. - Tevogen Bio's leadership emphasizes the importance of sustainability and commercial success through patient accessibility and innovative business models [3][4]. Leadership and Team - The company is led by a team of experienced industry leaders and distinguished scientists with expertise in drug development and global product launches [4]. - Tevogen Bio's leadership believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating disruptive business models to sustain medical innovation [4]. Market Position - Tevogen Bio has a market capitalization per team member that is 600% higher than the industry average, indicating a strong market position [7]. - The current ownership breakdown includes 79% insiders, 1% independent board members, 7% lead investors, 6% SPAC sponsors, and 8% others [7]. - The company's assets are believed to be valued in the billions, although these are not reflected on the balance sheet due to US GAAP restrictions on capitalizing internally developed intangible assets [7].

Core Viewpoint - Tevogen Bio aims to set new efficiency standards in the biotech industry, demonstrating that innovation and cost-effectiveness can coexist while addressing rising drug development costs and aligning with drug price reform efforts [1][2]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified precision T cell therapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases and cancers, targeting significant unmet needs in large patient populations [3]. - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents, with a focus on artificial intelligence [3]. Leadership and Business Model - Tevogen Bio is led by a team of experienced industry leaders and scientists with expertise in drug development and global product launches, emphasizing the need for accessible personalized therapeutics and disruptive business models to sustain medical innovation [4]. - The company’s business model challenges traditional biotech financing norms to ensure long-term sustainability and patient accessibility through advanced science [1][4]. Market Position - Tevogen Bio has a market capitalization per team member that is 600% higher than the industry average, indicating a strong market position [7]. - The current ownership breakdown includes 79% insiders, 1% independent board members, 7% lead investors, 6% SPAC sponsors, and 8% others, suggesting a solid backing from key stakeholders [7]. Future Outlook - The company plans to expand its efforts in artificial intelligence and develop additional product candidates, reflecting its commitment to innovation in the healthcare sector [5]. - Tevogen Bio's assets are believed to be valued in the billions, although these are not reflected on the balance sheet due to accounting regulations [7].

Core Viewpoint - Tevogen Bio emphasizes its commitment to preserving equity for shareholders while exploring financing strategies in the biotech sector, focusing on efficiency, asset ownership, and a path to revenue [1][2]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company that develops off-the-shelf, genetically unmodified precision T cell therapies targeting infectious diseases and cancers, addressing significant unmet needs in large patient populations [2]. - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents, with two related to artificial intelligence [2]. Leadership and Strategy - Tevogen Bio is led by a team of experienced industry leaders and scientists with expertise in drug development and global product launches, believing that accessible personalized therapeutics represent the next frontier of medicine [3]. - The company advocates for disruptive business models to sustain medical innovation and ensure patient accessibility through advanced science [3]. Financial Position - Tevogen Bio's assets are valued in the billions, although this value is not reflected on its balance sheet due to US GAAP restrictions on capitalizing internally developed intangible assets [5]. - The company's market cap per employee is approximately 600% higher than the industry average, indicating strong operational efficiency [5]. - Tevogen has a self-sustaining financing strategy, with multiple avenues to secure funds without selling equity, aiming for long-term sustainability [5]. Business Model - Tevogen's business model challenges traditional biotech financing norms, focusing on making advanced immunotherapies accessible and affordable [5]. - The company believes that its true value will become more recognized as awareness grows, and encourages employee ownership as a means to align interests [5].

Core Viewpoint - Tevogen Bio has successfully secured strategic financing and grant funding, reflecting confidence in its innovative business model and commitment to developing accessible, personalized T cell therapies for large patient populations [2][3][4]. Financing Activity - Tevogen Bio received $2 million from a grant agreement on January 28, 2025, with the potential for an additional $8 million based on future evaluations [2]. - The company signed a letter of intent on October 29 to establish a research and development facility valued at up to $50 million, which will not dilute existing shareholders [7]. - On August 15, 2024, Tevogen Bio completed a $6 million Series C Preferred Stock investment, featuring a 7.5% annual dividend and convertible into common stock after six months [7]. - A financing agreement was made on June 11 for up to $50 million, including a $36 million line of credit and a $14 million contingent private placement [7]. - An $8 million Series A Preferred Stock investment was secured on February 15, 2024, coinciding with the company's public debut [7]. Company Overview - Tevogen Bio specializes in developing off-the-shelf, genetically unmodified precision T cell therapies targeting infectious diseases, cancers, and neurological disorders [4]. - The company emphasizes sustainability and patient accessibility as key components of its business model, aiming to address significant unmet medical needs [4][5]. - Tevogen Bio has reported positive safety data from its proof-of-concept clinical trials, and it owns all key intellectual property assets without third-party licensing [4]. Leadership and Vision - The leadership team at Tevogen Bio consists of experienced industry leaders and scientists with a strong background in drug development and global product launches [5]. - The company believes that accessible personalized therapeutics represent the next frontier in medicine, necessitating disruptive business models to sustain innovation [5].

Core Viewpoint - Tevogen Bio emphasizes the importance of addressing the challenges posed by short-selling on healthcare innovation and its commitment to advancing affordable medical solutions while maintaining transparency and fairness in the market [2][3][4]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing precision T cell therapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases and cancers, aiming to meet significant unmet medical needs [5]. - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and additional pending patents related to artificial intelligence [5]. Strategic Initiatives - Tevogen Bio has formed a collaboration with Microsoft to explore AI applications in biotechnology, which is part of its broader strategy to enhance its product pipeline and ensure patient accessibility [2][5]. - The leadership believes that sustainable healthcare innovation relies on advanced science and innovative business models to ensure patient access [5][6]. Market Position and Challenges - The company faces pressure on its share price despite its advancements, raising concerns about the impact of short-selling on its focus and priorities [2][3]. - Tevogen Bio's leadership advocates for fair market participation, emphasizing the need for transparency and fairness for retail investors [4].